Want to see EVFM full AI Analyst Report?
Evofem Biosciences (EVFM) Ratios
1,208 Followers
Evofem Biosciences Ratios
EVFM's free cash flow for Q2 2026 was $-3.14M. For the 2026 fiscal year, EVFM's free cash flow was increased by $0.00 and operating cash flow was $-3.14M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.18 | 0.17 | 0.13 | 0.14 | 0.22 |
| Quick Ratio | 0.17 | 0.15 | 0.10 | 0.08 | 0.16 |
| Cash Ratio | 0.01 | 0.01 | 0.01 | 0.03 | 0.06 |
| Solvency Ratio | 0.01 | -0.09 | 0.71 | -0.77 | -1.44 |
| Operating Cash Flow Ratio | -0.02 | -0.05 | -0.12 | -0.75 | -1.07 |
| Short-Term Operating Cash Flow Coverage | -0.04 | -0.08 | -0.21 | -1.07 | -1.35 |
| Net Current Asset Value | $ -74.43M | $ -81.44M | $ -67.85M | $ -84.26M | $ -111.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.69 | 1.93 | 4.11 | 2.83 | 2.72 |
| Debt-to-Equity Ratio | -0.79 | -0.65 | -0.65 | -0.99 | -1.16 |
| Debt-to-Capital Ratio | -3.66 | -1.82 | -1.87 | -105.85 | 7.18 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.29 | -0.33 | -0.16 | -0.35 | -0.43 |
| Debt Service Coverage Ratio | 0.04 | -0.15 | -0.37 | -1.25 | -1.52 |
| Interest Coverage Ratio | 0.55 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 46.28 | 48.04 | 140.07 | 17.62 | 2.21 |
| Interest Debt Per Share | 0.46 | 0.48 | 8.99 | 152.64 | 1656.91 |
| Net Debt to EBITDA | 26.14 | -6.54 | -2.66 | -0.83 | -0.65 |
| Profitability Margins | |||||
| Gross Profit Margin | 74.65% | 80.20% | 64.26% | 73.78% | 50.81% |
| EBIT Margin | 7.13% | -39.64% | -97.96% | -499.64% | -2023.30% |
| EBITDA Margin | 10.23% | -35.74% | -88.19% | -487.49% | -2010.89% |
| Operating Profit Margin | 7.13% | -39.64% | -97.96% | -499.64% | -2023.30% |
| Pretax Profit Margin | 1.95% | -45.76% | 290.90% | -455.27% | -2488.78% |
| Net Profit Margin | 1.94% | -45.76% | 290.81% | -455.53% | -2488.99% |
| Continuous Operations Profit Margin | 1.94% | -45.76% | 290.81% | -455.53% | -2488.99% |
| Net Income Per EBT | 99.49% | 100.00% | 99.97% | 100.06% | 100.01% |
| EBT Per EBIT | 27.31% | 115.42% | -296.95% | 91.12% | 123.01% |
| Return on Assets (ROA) | 1.93% | -37.24% | 501.98% | -304.80% | -482.67% |
| Return on Equity (ROE) | -0.56% | 12.43% | -79.66% | 106.82% | 206.07% |
| Return on Capital Employed (ROCE) | -2.23% | 13.55% | 28.83% | 122.51% | 175.30% |
| Return on Invested Capital (ROIC) | -14.24% | 71.75% | 96.21% | 12518.45% | -1035.58% |
| Return on Tangible Assets | 2.46% | -62.43% | 501.98% | -304.80% | -482.67% |
| Earnings Yield | 33.28% | -927.80% | 17150.15% | -2057.42% | -416.87% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.62 | 1.97 | 3.17 | 14.95 | 1.28 |
| Payables Turnover | 0.39 | 0.24 | 0.38 | 0.29 | 0.39 |
| Inventory Turnover | 4.53 | 2.43 | 3.84 | 0.82 | 0.53 |
| Fixed Asset Turnover | 33.64 | 35.40 | 13.92 | 2.02 | 0.74 |
| Asset Turnover | 1.00 | 0.81 | 1.73 | 0.67 | 0.19 |
| Working Capital Turnover Ratio | -0.30 | -0.30 | -0.25 | -0.18 | -0.19 |
| Cash Conversion Cycle | -632.15 | -1204.12 | -743.90 | -769.66 | 47.71 |
| Days of Sales Outstanding | 225.69 | 185.34 | 114.96 | 24.41 | 285.53 |
| Days of Inventory Outstanding | 80.55 | 150.13 | 95.12 | 444.70 | 690.75 |
| Days of Payables Outstanding | 938.40 | 1539.59 | 953.98 | 1238.77 | 928.57 |
| Operating Cycle | 306.24 | 335.47 | 210.08 | 469.11 | 976.28 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.04 | -1.86 | -151.10 | -2100.70 |
| Free Cash Flow Per Share | -0.02 | -0.04 | -1.86 | -151.83 | -2142.80 |
| Dividend Paid and CapEx Coverage Ratio | -16.33 | -277.50 | -2242.00 | -206.48 | -49.90 |
| Capital Expenditure Coverage Ratio | -398.40 | -277.50 | -2242.00 | -206.48 | -49.90 |
| Operating Cash Flow Coverage Ratio | -0.04 | -0.08 | -0.21 | -0.99 | -1.27 |
| Operating Cash Flow to Sales Ratio | -0.10 | -0.20 | -0.49 | -4.18 | -17.79 |
| Free Cash Flow Yield | -169.99% | -408.30% | -2904.38% | -1897.89% | -303.94% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 4.32 | -0.11 | 0.01 | -0.05 | -0.24 |
| Price-to-Sales (P/S) Ratio | 0.06 | 0.05 | 0.02 | 0.22 | 5.97 |
| Price-to-Book (P/B) Ratio | -0.02 | -0.01 | -0.00 | -0.05 | -0.49 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.59 | -0.24 | -0.03 | -0.05 | -0.33 |
| Price-to-Operating Cash Flow Ratio | -0.59 | -0.25 | -0.03 | -0.05 | -0.34 |
| Price-to-Earnings Growth (PEG) Ratio | -0.04 | 0.00 | -0.00 | 0.00 | 0.01 |
| Enterprise Value Multiple | 26.70 | -6.67 | -2.68 | -0.88 | -0.95 |
| Enterprise Value | 55.14M | 46.18M | 43.10M | 72.09M | 157.17M |
| EV to EBITDA | 26.70 | -6.67 | -2.68 | -0.88 | -0.95 |
| EV to Sales | 2.73 | 2.39 | 2.37 | 4.28 | 19.06 |
| EV to Free Cash Flow | -27.61 | -11.84 | -4.80 | -1.02 | -1.05 |
| EV to Operating Cash Flow | -27.68 | -11.89 | -4.81 | -1.02 | -1.07 |
| Tangible Book Value Per Share | -0.60 | -0.84 | -13.78 | -154.08 | -1426.21 |
| Shareholders’ Equity Per Share | -0.56 | -0.74 | -13.78 | -154.08 | -1426.21 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.00 | 0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.16 | 0.20 | 3.77 | 36.13 | 118.08 |
| Net Income Per Share | 0.00 | -0.09 | 10.98 | -164.59 | -2938.96 |
| Tax Burden | 0.99 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.27 | 1.15 | -2.97 | 0.91 | 1.23 |
| Research & Development to Revenue | 0.17 | 0.10 | 0.16 | 1.49 | 4.02 |
| SG&A to Revenue | 0.85 | 1.07 | 0.82 | 1.64 | 3.00 |
| Stock-Based Compensation to Revenue | 0.01 | 0.04 | 0.07 | 0.20 | 1.08 |
| Income Quality | -7.27 | 0.44 | -0.17 | 0.92 | 0.71 |
Currency in USD
